FDA Approves Bristol Myers' Iberdomide Combo for Multiple Myeloma
BMY sits 52% above its 52-week low of $42.52.
Summary
The FDA granted accelerated approval to iberdomide (Zenbexus) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma, as early as first relapse. This is a new regulatory milestone for Bristol Myers Squibb's oncology portfolio, expanding its multiple myeloma franchise. The approval follows positive late-stage data for the company's oral drug mezigdomide in May and a strong Q2 earnings beat in July. Accelerated approval allows earlier market entry, potentially adding a meaningful revenue stream. The company's stock is trading near its 52-week high, reflecting investor optimism. Watch for confirmatory trial results and commercial launch details.
At the time of this announcement, BMY was trading at $64.82 on NYSE in the Life Sciences sector, with a market capitalization of approximately $132.1B. The 52-week trading range was $42.52 to $68.10. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.